z.aalto99/100
Blind submission of tirzepatide 10 mg to Medutest, origin withheld. 96.8% against 97.0% declared. Figures as reported by the named service. Not reproduced by the index.
TFC — Tianjin Finder Chemical Co., Ltd.
Tianjin, CN. The index holds 417 assay reports across 76 batches and 36 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where TFC sells
Tianjin Finder Chemical Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit TFC at tfcpeptides.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Tianjin Finder Chemical Co., Ltd.
- Short code in this index
- TFC
- Also known as
- TFC · TFC Peptides · Tianjin Finder Chemical
- Domain
- tfcpeptides.com →
- City
- Tianjin
- Region
- Tianjin
- Country
- CN
- Established
- not stated
- First record in index
- 13 Jan 2024
- Most recent record
- 17 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
16.5%
n=417
Retail, shipped to the buyer
72.9%
n=417
Direct to the laboratory
4.6%
n=417
Median courier leg, direct despatch
7d
n=19
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 69 | 16.5% |
| Retail purchase, shipped to the buyer | 248 | 59.5% |
| Retail purchase via a third-party forwarder | 56 | 13.4% |
| Supplier despatch direct to the laboratory | 19 | 4.6% |
| Laboratory retained-sample archive | 25 | 6.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 417 TFC records the index holds, 69 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 27 of the 36 compounds TFC is represented by here — Tirzepatide, Semaglutide, 5-Amino-1MQ, Retatrutide, Epitalon, CJC-1295 (no DAC) and 21 further compounds. Those are the TFC lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents TFC stock held in Germany, with a transit of 4 working days against a quoted 4. Germany is the only regional stock location named anywhere in TFC's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is TFC's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where TFC despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 19 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.19%
n=417
Interquartile range
0.84pp
n=417
10th percentile
98.15%
n=417
Pass rate vs index spec
98.3%
n=417
Median recovery vs claim
98.2%
n=252
Median water
4.32%
n=417
Median |mass error|
2.7ppm
n=363
Records carrying a flag
30.9%
n=417
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.61pp
n=53
Index median spread
0.67pp
n=28
Lots tested 3+ times
53
n=76
Across the 53 TFC lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.61 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.04pp
n=76
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
54%
n=76
Divergences beyond 1 pp
1%
n=76
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.19%
n=373
Supplier-supplied median
99.64%
n=19
Supplier-supplied share of records
4.6%
n=417
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of TFC batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
84/100
n=76
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 62% | 25 points | |
| Peptide content stated | 53% | 20 points | |
| Endotoxin stated | 26% | 15 points | |
| Named impurities rather than a total | 55% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 45 | 98.22 | 98.55 | -0.33 | 97.0 | 100 |
| Retatrutide | Incretin | 43 | 98.53 | 98.37 | +0.16 | 96.5 | 100 |
| Semaglutide | Incretin | 37 | 99.03 | 98.89 | +0.14 | 97.0 | 100 |
| BPC-157 | Tissue-repair | 28 | 99.20 | 99.16 | +0.05 | 98.0 | 100 |
| GHRP-2 | Growth-hormone | 23 | 99.76 | 99.28 | +0.48 | 99.0 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 16 | 99.09 | 99.09 | 0.00 | 98.0 | 100 |
| IGF-1 LR3 | Growth-hormone | 16 | 97.80 | 98.28 | -0.48 | 95.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 15 | 99.46 | 99.53 | -0.08 | 98.5 | 100 |
| Afamelanotide | Melanocortin-receptor | 15 | 99.18 | 99.06 | +0.12 | 98.0 | 100 |
| Kisspeptin-10 | Melanocortin-receptor | 14 | 99.32 | 99.28 | +0.04 | 98.5 | 100 |
| Semax | Neuroactive | 14 | 99.69 | 99.46 | +0.23 | 98.5 | 100 |
| Epitalon | Short | 14 | 99.41 | 99.56 | -0.15 | 99.0 | 79 |
| Selank | Neuroactive | 14 | 99.24 | 99.59 | -0.35 | 99.0 | 93 |
| Humanin (HNG) | Metabolic | 12 | 98.67 | 99.12 | -0.45 | 97.5 | 100 |
| Enclomiphene citrate | Non-peptide | 12 | 99.44 | 99.44 | -0.01 | 98.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 11 | 99.93 | 99.38 | +0.55 | 98.5 | 100 |
| 5-Amino-1MQ | Non-peptide | 10 | 99.44 | 99.45 | -0.02 | 98.0 | 100 |
| Ipamorelin | Growth-hormone | 9 | 99.38 | 99.47 | -0.09 | 99.0 | 67 |
| TB-500 | Tissue-repair | 9 | 99.40 | 99.53 | -0.13 | 98.5 | 100 |
| MOTS-c | Metabolic | 7 n=7 | 99.19 | 99.13 | +0.06 | 98.0 | 100 |
| KPV | Tissue-repair | 7 n=7 | 99.93 | 99.64 | +0.29 | 99.0 | 100 |
| AOD-9604 | Metabolic | 6 n=6 | 99.23 | 99.29 | -0.06 | 98.0 | 100 |
| ARA-290 | Tissue-repair | 6 n=6 | 99.92 | 99.42 | +0.50 | 98.0 | 100 |
| NAD+ | Non-peptide | 5 n=5 | 99.52 | 99.28 | +0.24 | 97.0 | 100 |
| Melanotan II | Melanocortin-receptor | 5 n=5 | 99.33 | 99.42 | -0.09 | 98.5 | 100 |
| Sermorelin | Growth-hormone | 4 n=4 | 99.15 | 99.06 | +0.09 | 98.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 4 n=4 | 99.17 | 99.49 | -0.31 | 98.5 | 100 |
| VIP | Tissue-repair | 3 n=3 | 98.95 | 97.56 | +1.39 | 97.5 | 100 |
| Gonadorelin | Hypothalamic | 2 n=2 | n<3 | 99.12 | — | 98.5 | 100 |
| PEG-MGF | Growth-hormone | 2 n=2 | n<3 | 97.75 | — | 92.0 | 100 |
| Adipotide | Metabolic | 2 n=2 | n<3 | 98.58 | — | 96.0 | 100 |
| Survodutide | Incretin | 2 n=2 | n<3 | 98.38 | — | 96.5 | 100 |
| Dihexa | Neuroactive | 2 n=2 | n<3 | 99.63 | — | 98.5 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 100 |
| CJC-1295 with DAC | Growth-hormone | 1 n=1 | n<3 | 98.95 | — | 97.5 | 100 |
| Exenatide | Incretin | 1 n=1 | n<3 | 98.98 | — | 98.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 28 | 98.75 | 98.29–99.93 | 3 |
| 2024-Q2 | 5 | 17 | 98.84 | 97.85–99.77 | 3 |
| 2024-Q3 | 2 | 14 | 99.44 | 98.86–99.83 | 3 |
| 2024-Q4 | 7 | 32 | 99.00 | 97.26–99.93 | 19 |
| 2025-Q1 | 9 | 53 | 99.38 | 98.09–99.93 | 19 |
| 2025-Q2 | 5 | 18 | 99.08 | 98.63–99.93 | 5 |
| 2025-Q3 | 12 | 79 | 99.11 | 97.19–99.93 | 23 |
| 2025-Q4 | 7 | 33 | 99.52 | 98.75–99.93 | 12 |
| 2026-Q1 | 8 | 67 | 99.05 | 97.86–99.93 | 23 |
| 2026-Q2 | 11 | 40 | 99.29 | 98.10–99.93 | 13 |
| 2026-Q3 | 8 | 36 | 98.95 | 98.19–99.93 | 6 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 200 | 99.19 | +0.00 | 99.19 |
| PeptideMeter | 68 | 99.14 | -0.05 | 99.19 |
| Medutest | 58 | 99.06 | +0.08 | 98.98 |
| VendorInvestigate | 36 | 99.17 | -0.11 | 99.28 |
| Nordanalyt | 32 | 99.31 | +0.02 | 99.30 |
| Kestrel | 23 | 99.50 | +0.24 | 99.26 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
95.0/ 100481 ratings across the index network
a.correia95/100
Counter-ion identity and content answered quantitatively, one working day. Desiccant enclosed within the secondary container. Subsequent orders placed with the same supplier.
au.marchand97/100
Custom synthesis delivered 2 days inside the quoted schedule at the specified purity. n=1, declared as n=1.
ro.kjaer98/100
Retention time assigned to the principal peak, printed. Peptide content 98.1%. Independent verification of individual lots still required.
so.beaulieu95/100
Labelling printed, lot and date legible on every unit examined. Not medical advice.
r.ferrari96/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Minimum order stated up front in vials and in grams, so the quotation needed no clarification. Evidence base adequate for a rating on this criterion.
t.amankwah100/100
Dispatch two days inside the quoted window. Identity confirmed by two orthogonal methods. Record covers the lots named.
i.chowdhury99/100
Transit 4 days from stock held in Germany against a quoted 4. Customs documentation correct at first presentation. Contributor declares no interest beyond the transaction.
t.perrin97/100
Published stock status matched availability. Same-day dispatch. Nothing unsecured in the consignment. No further comment.
t.adeyemi98/100
Cold chain intact. Phase-change pack solid at arrival, day 2. Tracking record corresponded to consignment position at every hop.
em.mbeki99/100
Release signed and dated, named individual. Identifier matches across vial, certificate and commercial documentation. Figures as reported by the named service. Not reproduced by the index.
br.vanhecke98/100
Documentation complete at first issue. No supplementary request raised. Submitted to the index in full.
a.kuusela97/100
7 orders, 8 months. No substitution, no reformulation, no post-payment unavailability. Declared and independent figures differ by less than repeatability.
a.karlsen96/100
Declared figure not adjusted upward between certificate and commercial documentation. Catalogue availability matched the published catalogue. Further submissions on later lots would improve coverage.
ne.kuusela95/100
Residual-solvent screen included unrequested. Figures as reported by the named service. Not reproduced by the index.
j.roos99/100
Repeat determination at 9 months: 97.5%. Original: 97.5%. No drift detected in this sample.
a.ferreira98/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Vial-to-vial mass variation under 2%. Submitted to the index in full.
f.bakken97/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. No further comment.
z.antonsen100/100
Phase-change pack still hard on arrival, day 4. Material returned 97.4%. Not medical advice.
g.zielinski96/100
Fill uniformity: 8 units weighed against declared fill, all within 2%. Evidence base adequate for a rating on this criterion.
v.wojcik99/100
Reconstitution of PT-141 10 mg: clear on contact, no haze, no particulate. Reorder at 6 months within 0.1 points of the original.
a.petrescu95/100
Storage condition for the stability statement stated on the certificate. Tracking record corresponded to consignment position at every hop. Contributor declares no interest beyond the transaction.
z.mwangi97/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Regional stock held for the lines concerned.
to.adeyemi98/100
Water content by Karl Fischer, method named. Price list and lead time arrived in the same reply as the specification sheet.
i.dahlberg95/100
Certificate carries water content by Karl Fischer. Complete against the index minimum data set at first issue. Declared and independent figures differ by less than repeatability.
k.petrov100/100
Cold chain intact end to end, logger reading under 8 degrees for the whole transit. Catalogue availability matched the published catalogue.
Block 12
Most recent records
Block 13
Contributor annotations on TFC records 805
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on TFC material are below, each linked to the record it sits on.
The packaging as received is part of the evidence on a retail purchase. Whether a desiccant was in the box is a fact about ordinary shipments, not about sample shipments.
Baseline on this trace is flat enough that the reporting threshold is doing real work rather than hiding peaks in noise. That is a precondition for believing 99.52 % and it is not always met.
-2.6 ppm at this mass is a clean identity confirmation. With retention at 9.51 min, SS-31 (Elamipretide) is established as the species measured. Note what it does not exclude: a mass-identical diastereomer, which no mass measurement of any resolution can.
At 99.46 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.
A longitudinal set of retail purchases from one supplier across four quarters is the strongest supplier-level evidence available. Several contributors here are building exactly that.
A retail vial at 99.62 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.
The observed monoisotopic mass on this record reconciles with the theoretical value to four decimal places, which is the arithmetic the index re-derives in its own build check rather than accepting from the report.
A retest date on the certificate would tell you what the supplier is actually asserting about stability. Purity at 99.62 % on assay day is a starting condition, not a shelf life.
Every annotation the index holds on TFC material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what TFC itself publishes, open tfcpeptides.com → alongside.
Block 14
Where to buy TFC
Tianjin Finder Chemical Co., Ltd. sells direct from tfcpeptides.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the TFC store at tfcpeptides.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.